Microglial dysfunction connects depression and Alzheimer's disease

Brain, Behavior, and Immunity

Volumn 55, Issue , 2016, Pages 151-165

  Santos, Luís Eduardo ^a   Beckman, Danielle ^a   Ferreira, Sergio T ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Alzheimer's disease; Major depressive disorder; Microglia; Neuroinflammation

Indexed keywords

ALPHA INTERFERON; AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE RECEPTOR CX3CR1; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; SEROTONIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELL SELF-RENEWAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INCIDENCE; INNATE IMMUNITY; MAJOR DEPRESSION; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TRAUMATIC BRAIN INJURY; ANIMAL; DEPRESSION; IMMUNOLOGY;

ALZHEIMER DISEASE; ANIMALS; DEPRESSION; HUMANS; MICROGLIA;

EID: 84961194024     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.11.011     Document Type: Article

References (290)

1. Aarum, J., Sandberg, K., Haeberlein, S.L.B., Persson, M.A.A., Migration and differentiation of neural precursor cells can be directed by microglia. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 15983–15988, 10.1073/pnas.2237050100.
2. Adlard, P.A., Perreau, V.M., Pop, V., Cotman, C.W., Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005), 4217–4221, 10.1523/JNEUROSCI.0496-05.2005.
3. Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W., Rossi, F.M.V., Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10 (2007), 1538–1543, 10.1038/nn2014.
4. Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A.A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., Kamalipour, A., Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 26 (2009), 607–611, 10.1002/da.20589.
5. Alesci, S., Martinez, P.E., Kelkar, S., Ilias, I., Ronsaville, D.S., Listwak, S.J., Ayala, A.R., Licinio, J., Gold, H.K., Kling, M.A., Chrousos, G.P., Gold, P.W., Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 90 (2005), 2522–2530, 10.1210/jc.2004-1667.
6. Allegri, R.F., Sarasola, D., Serrano, C.M., Taragano, F.E., Arizaga, R.L., Butman, J., Loñ, L., Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease. Neuropsychiatr. Dis. Treat. 2 (2006), 105–110.
7. Álvarez, A., Cacabelos, R., Sanpedro, C., García-Fantini, M., Aleixandre, M., Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging 28 (2007), 533–536, 10.1016/j.neurobiolaging.2006.02.012.
8. Anisman, H., Hayley, S., Inflammatory factors contribute to depression and its comorbid conditions. Sci. Signal., 5, 2012, 10.1126/scisignal.2003579 pe45–pe45.
9. Apostolova, L.G., Cummings, J.L., Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement. Geriatr. Cogn. Disord. 25 (2008), 115–126 000112509 [pii] 10.1159/000112509.
10. Baalman, K., Marin, M.A., Ho, T.S.-Y., Godoy, M., Cherian, L., Robertson, C., Rasband, M.N., Axon initial segment-associated microglia. J. Neurosci. 35 (2015), 2283–2292, 10.1523/JNEUROSCI.3751-14.2015.
11. Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., Knapp, M., Lawton, C., Lindesay, J., Livingston, G., McCrae, N., Moniz-Cook, E., Murray, J., Nurock, S., Orrell, M., O'Brien, J., Poppe, M., Thomas, A., Walwyn, R., Wilson, K., Burns, A., Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378 (2011), 403–411, 10.1016/S0140-6736(11)60830-1.
12. Barnabé-Heider, F., Miller, F.D., Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J. Neurosci. 23 (2003), 5149–5160.
13. Beckman, D., Santos, L.E., The importance of serotonin in exercise-induced adult neurogenesis: new evidence from Tph2−/− mice. J. Neurosci. 33 (2013), 14283–14284, 10.1523/JNEUROSCI.2911-13.2013.
14. Benoit, M., Berrut, G., Doussaint, J., Bakchine, S., Bonin-Guillaume, S., Frémont, P., Gallarda, T., Krolak-Salmon, P., Marquet, T., Mékiès, C., Sellal, F., Schuck, S., David, R., Robert, P., Apathy and depression in mild Alzheimer's disease: a cross-sectional study using diagnostic criteria. J. Alzheimers. Dis. 31 (2012), 325–334, 10.3233/JAD-2012-112003.
15. Berton, O., Nestler, E.J., New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7 (2006), 137–151, 10.1038/nrn1846.
16. Bluthé, R.-M., Kelley, K.W., Dantzer, R., Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice. Brain Behav. Immun. 20 (2006), 57–63, 10.1016/j.bbi.2005.02.003.
17. Bocchio-Chiavetto, L., Bagnardi, V., Zanardini, R., Molteni, R., Nielsen, M.G., Placentino, A., Giovannini, C., Rillosi, L., Ventriglia, M., Riva, M.A., Gennarelli, M., Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry 11 (2010), 763–773, 10.3109/15622971003611319.
18. Bockaert, J., Claeysen, S., Compan, V., Dumuis, A., 5-HT4 receptors: history, molecular pharmacology and brain functions. Neuropharmacology 55 (2008), 922–931, 10.1016/j.neuropharm.2008.05.013.
19. Boldrini, M., Hen, R., Underwood, M.D., Rosoklija, G.B., Dwork, A.J., Mann, J.J., Arango, V., Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol. Psychiatry 72 (2012), 562–571, 10.1016/j.biopsych.2012.04.024.
20. Boldrini, M., Santiago, A.N., Hen, R., Dwork, A.J., Rosoklija, G.B., Tamir, H., Arango, V., John Mann, J., Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology 38 (2013), 1068–1077, 10.1038/npp.2013.5.
21. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., De Felice, F.G., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest. 122 (2012), 1339–1353, 10.1172/JCI57256.
22. Bonda, D.J., Mailankot, M., Stone, J.G., Garrett, M.R., Staniszewska, M., Castellani, R.J., Siedlak, S.L., Zhu, X., Lee, H., Perry, G., Nagaraj, R.H., Smith, M.A., Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 15 (2010), 161–168, 10.1179/174329210X12650506623645.
23. Bremner, J.D., Narayan, M., Anderson, E.R., Staib, L.H., Miller, H.L., Charney, D.S., Hippocampal volume reduction in major depression. Am. J. Psychiatry 157 (2000), 115–118, 10.1176/appi.ajp.157.1.115.
24. Bufalino, C., Hepgul, N., Aguglia, E., Pariante, C.M., The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav. Immun. 31 (2013), 31–47, 10.1016/j.bbi.2012.04.009.
25. Burns, A., Jacoby, R., Levy, R., Psychiatric phenomena in Alzheimer's disease. III. Disorders of mood. Br. J. Psychiatry 157 (1990), 81–86, 10.1192/bjp.157.1.81.
26. Burns, A., Jacoby, R., Levy, R., Psychiatric phenomena in Alzheimer's disease. IV. Disorders of behaviour. Br. J. Psychiatry 157 (1990), 86–94, 10.1192/bjp.157.1.86.
27. Butters, M.A., Young, J.B., Lopez, O., Aizenstein, H.J., Mulsant, B.H., Reynolds, C.F., DeKosky, S.T., Becker, J.T., Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin. Neurosci. 10 (2008), 345–357, 10.1016/j.bbi.2008.05.010.
28. Cannon, J.P., O'Driscoll, M., Litman, G.W., Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics 64 (2012), 39–47, 10.1007/s00251-011-0562-4.
29. Carro, E., Torres-Aleman, I., Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?. Expert Rev. Neurother. 4 (2004), 79–86, 10.1586/14737175.4.1.79.
30. Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., Torres-Aleman, I., Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002), 1390–1397, 10.1038/nm793.
31. Carvalho, A.F., Miskowiak, K.K., Hyphantis, T.N., Köhler, C.A., Alves, G.S., Bortolato, B., Sales, P.M.G., Machado-vieira, R., Berk, M., Mcintyre, R.S., Cognitive dysfunction in depression – pathophysiology and novel targets. CNS Neurol. Disord.: Drug Targets 13 (2014), 1819–1835.
32. Casano, A.M., Peri, F., Microglia: multitasking specialists of the brain. Dev. Cell 32 (2015), 469–477, 10.1016/j.devcel.2015.01.018.
33. Cassilhas, R.C., Antunes, H.K.M., Tufik, S., de Mello, M.T., Mood, anxiety, and serum IGF-1 in elderly men given 24 weeks of high resistance exercise. Percept. Mot. Skills 110 (2010), 265–276, 10.2466/PMS.110.1.265-276.
34. Chakrabarty, P., Li, A., Das, P., Golde, T.E., Chakrabarty, P., Li, A., Ceballos-diaz, C., Eddy, J.A., Funk, C.C., Moore, B., Dinunno, N., Rosario, A.M., Cruz, P.E., Verbeeck, C., Sacino, A., Nix, S., IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive article IL-10 alters immunoproteostasis in APP Mice, increasing plaque burden and worsening cognitive behavior. Neuron 85 (2015), 519–533, 10.1016/j.neuron.2014.11.020.
35. Chang, K.A., Kim, J.A., Kim, S.S., Joo, Y., Shin, K.Y., Kim, S.S., Kim, H.S., Suh, Y.H., Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer's disease. Neurochem. Int. 61 (2012), 885–891, 10.1016/j.neuint.2012.03.017.
36. Chemerinski, E., Petracca, G., Sabe, L., Kremer, J., Starkstein, S.E., The specificity of depressive symptoms in patients with Alzheimer's disease. Am. J. Psychiatry 158 (2001), 68–72, 10.1176/appi.ajp.158.1.68.
37. Chen, Z., Trapp, B.D., Microglia and neuroprotection. J. Neurochem., 1–8, 2015, 10.1111/jnc.13062.
38. Chen, S.Y., Chen, T.F., Lai, L.C., Chen, J.H., Sun, Y., Wen, L.L., Yip, P.K., Chu, Y.M., Chen, Y.C., Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease. J. Neuroinflamm., 9, 2012, 21, 10.1186/1742-2094-9-21.
39. Cherry, J.D., Olschowka, J.A., O'Banion, M.K., Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflamm., 11, 2014, 98, 10.1186/1742-2094-11-98.
40. Chi, S., Yu, J.-T., Tan, M.-S., Tan, L., Depression in Alzheimer's disease: epidemiology, mechanisms, and management. J. Alzheimers. Dis. 42 (2014), 739–755, 10.3233/JAD-140324.
41. Chi, S., Wang, C., Jiang, T., Zhu, X.-C., Yu, J.-T., Tan, L., The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. Curr. Alzheimer Res. 12 (2015), 189–198.
42. Choi, S., Li, Y., Parada, L.F., Sisodia, S.S., Regulation of hippocampal progenitor cell survival, proliferation and dendritic development by BDNF. Mol. Neurodegener., 4, 2009, 52, 10.1186/1750-1326-4-52.
43. Chow, T.W., Pollock, B.G., Milgram, N.W., Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr. Dis. Treat. 3 (2007), 627–636.
44. Cirrito, J.R., Disabato, B.M., Restivo, J.L., Verges, D.K., Goebel, W.D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., Kim, J., Morris, J.C., Mintun, M.A., Sheline, Y.I., Serotonin signaling is associated with lower amyloid-{beta} levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 14968–14973, 10.1073/pnas.1107411108.
45. Clark, C.M., Schneider, J.A., Bedell, B.J., Beach, T.G., Bilker, W.B., Mintun, M.A., Pontecorvo, M.J., Hefti, F., Carpenter, A.P., Flitter, M.L., Krautkramer, M.J., Kung, H.F., Coleman, R.E., Doraiswamy, P.M., Fleisher, A.S., Sabbagh, M.N., Sadowsky, C.H., Reiman, E.P., Zehntner, S.P., Skovronsky, D.M., Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305 (2011), 275–283, 10.1001/jama.2010.2008.
46. Colonna, M., TREMs in the immune system and beyond. Nat. Rev. Immunol. 3 (2003), 445–453, 10.1038/nri1106.
47. Condello, C., Yuan, P., Schain, A., Grutzendler, J., Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat. Commun., 6, 2015, 6176, 10.1038/ncomms7176.
48. Coppen, A., The biochemistry of affective disorders. Br. J. Psychiatry 113 (1967), 1237–1264, 10.1192/bjp.113.504.1237.
49. Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994), 2308–2314, 10.1212/WNL.44.12.2308.
50. Cunningham, C., Microglia and neurodegeneration: the role of systemic inflammation. Glia 61 (2013), 71–90, 10.1002/glia.22350.
51. Curtis, C., Gamez, J.E., Singh, U., Al, E., Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 72 (2015), 287–294.
52. Dai, L., Liu, D., Guo, H., Wang, Y., Bai, Y., Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis. J. Neurol. 259 (2012), 414–419, 10.1007/s00415-011-6164-0.
53. Dantzer, R., Walker, A.K., Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?. J. Neural Transm., 925–932, 2014, 10.1007/s00702-014-1187-1.
54. Dantzer, R., Gheusi, G., Johnson, R.W., Kelley, K.W., Central administration of insulin-like growth factor-1 inhibits lipopolysaccharide-induced sickness behavior in mice. NeuroReport 10 (1999), 289–292.
55. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56, 10.1038/nrn2297.
56. De Felice, F.G., Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 123 (2013), 531–539, 10.1172/JCI64595.
57. De Felice, F.G., Ferreira, S.T., Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63 (2014), 2262–2272, 10.2337/db13-1954.
58. De Felice, F.G., Lourenco, M.V., Ferreira, S.T., How does brain insulin resistance develop in Alzheimer's disease?. Alzheimer's Dement. 10 (2014), S26–S32, 10.1016/j.jalz.2013.12.004.
59. Dean, O.M., Data-Franco, J., Giorlando, F., Berk, M., Minocycline: therapeutic potential in psychiatry. CNS Drugs 26 (2012), 391–401, 10.2165/11632000-000000000-00000.
60. Dean, O.M., Maes, M., Ashton, M., Berk, L., Kanchanatawan, B., Sughondhabirom, A., Tangwongchai, S., Ng, C., Dowling, N., Malhi, G.S., Berk, Mi., Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin. Psychopharmacol. Neurosci. 12 (2014), 180–188, 10.9758/cpn.2014.12.3.180.
61. Demars, M., Hu, Y.-S., Gadadhar, A., Lazarov, O., Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J. Neurosci. Res. 88 (2010), 2103–2117, 10.1002/jnr.22387.
62. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D., Rosenberg, S.A., The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107 (1987), 293–300.
63. Doecke, J.D., Laws, S.M., Faux, N.G., Wilson, W., Burnham, S.C., Lam, C.-P., Mondal, A., Bedo, J., Bush, A.I., Brown, B., De Ruyck, K., Ellis, K.A., Fowler, C., Gupta, V.B., Head, R., Macaulay, S.L., Pertile, K., Rowe, C.C., Rembach, A., Rodrigues, M., Rumble, R., Szoeke, C., Taddei, K., Taddei, T., Trounson, B., Ames, D., Masters, C.L., Martins, R.N., Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69 (2012), 1318–1325, 10.1001/archneurol.2012.1282.
64. Doens, D., Fernández, P.L., Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis. J. Neuroinflamm., 11, 2014, 48, 10.1186/1742-2094-11-48.
65. Dougherty, K.D., Dreyfus, C.F., Black, I.B., Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury. Neurobiol. Dis. 7 (2000), 574–585, 10.1006/nbdi.2000.0318.
66. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457, 10.1016/j.biopsych.2009.09.033.
67. Dunger, D.B., Ong, K.K.L., Sandhu, M.S., Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes. Horm. Res. 60:Suppl. 3 (2003), 131–135, 10.1159/000074514.
68. Dwivedi, Y., Involvement of brain-derived neurotrophic factor in late-life depression. Am. J. Geriatr. Psychiatry 21 (2013), 433–449, 10.1016/j.jagp.2012.10.026.
69. Ekdahl, C.T., Claasen, J.-H., Bonde, S., Kokaia, Z., Lindvall, O., Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 13632–13637, 10.1073/pnas.2234031100.
70. El Khoury, J., Toft, M., Hickman, S.E., Means, T.K., Terada, K., Geula, C., Luster, A.D., Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13 (2007), 432–438, 10.1038/nm1555.
71. Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.M., Nordborg, C., Peterson, D.A., Gage, F.H., Neurogenesis in the adult human hippocampus. Nat. Med. 4 (1998), 1313–1317, 10.1038/3305.
72. Eyre, H.A., Papps, E., Baune, B.T., Treating Depression and Depression-Like Behavior with Physical Activity: An Immune Perspective. Front. Psychiatry 4 (2013), 1–27, 10.3389/fpsyt.2013.00003.
73. Felger, J.C., Lotrich, F.E., Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246 (2013), 199–229, 10.1016/j.neuroscience.2013.04.060.
74. Fenn, A.M., Hall, J.C.E., Gensel, J.C., Popovich, P.G., Godbout, J.P., IL-4 signaling drives a unique arginase+/IL-1+ microglia phenotype and recruits macrophages to the inflammatory CNS: consequences of age-related deficits in IL-4R after traumatic spinal cord injury. J. Neurosci. 34 (2014), 8904–8917, 10.1523/JNEUROSCI.1146-14.2014.
75. Ferreira, S.T., Klein, W.L., The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 96 (2011), 529–543, 10.1016/j.nlm.2011.08.003.
76. Ferreira, S.T., Vieira, M.N.N., De Felice, F.G., Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59 (2007), 332–345, 10.1080/15216540701283882.
77. Ferreira, S.T., Clarke, J.R., Bomfim, T.R., De Felice, F.G., Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimer's Dement. 10 (2014), S76–S83, 10.1016/j.jalz.2013.12.010.
78. Figueiredo, C.P., Clarke, J.R., Ledo, J.H., Ribeiro, F.C., Costa, C.V., Melo, H.M., Mota-Sales, A.P., Saraiva, L.M., Klein, W.L., Sebollela, A., De Felice, F.G., Ferreira, S.T., Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J. Neurosci. 33 (2013), 9626–9634, 10.1523/JNEUROSCI.0482-13.2013.
79. Fiske, A., Wetherell, J.L., Gatz, M., Depression in older adults. Annu. Rev. Clin. Psychol. 5 (2009), 363–389, 10.1146/annurev.clinpsy.032408.153621.
80. Frank, S., Burbach, G.J., Bonin, M., Walter, M., Streit, W., Bechmann, I., Deller, T., TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56 (2008), 1438–1447, 10.1002/glia.20710.
81. Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R.C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., Cummings, J.L., de Leon, M., Feldman, H., Ganguli, M., Hampel, H., Scheltens, P., Tierney, M.C., Whitehouse, P., Winblad, B., Mild cognitive impairment. Lancet 367 (2006), 1262–1270, 10.1016/S0140-6736(06)68542-5.
82. Geldenhuys, W.J., der Schyf, C.J., Van Der Schyf, C.J., der Schyf, C.J., Role of serotonin in Alzheimer's disease: a new therapeutic target?. CNS Drugs 25 (2011), 765–781, 10.2165/11590190-000000000-00000.
83. Gemma, C., Bachstetter, A.D., The role of microglia in adult hippocampal neurogenesis. Front. Cell. Neurosci., 7, 2013, 229, 10.3389/fncel.2013.00229.
84. Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., Conway, S.J., Ng, L.G., Stanley, E.R., Samokhvalov, I.M., Merad, M., Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330 (2010), 841–845, 10.1126/science.1194637.
85. Glebov, K., Löchner, M., Jabs, R., Lau, T., Merkel, O., Schloss, P., Steinhäuser, C., Walter, J., Serotonin stimulates secretion of exosomes from microglia cells. Glia 63 (2015), 626–634, 10.1002/glia.22772.
86. Gleeson, M., Bishop, N.C., Stensel, D.J., Lindley, M.R., Mastana, S.S., Nimmo, M.A., The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11 (2011), 607–615, 10.1038/nri3041.
87. Gong, C.Y., Li, Z., Wang, H.M., Liu, J., Chen, L., Zhang, H.W., Wang, X., Yang, J., Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease. Med. Hypotheses 77 (2011), 383–385, 10.1016/j.mehy.2011.05.022.
88. Grassi-Oliveira, R., Brietzke, E., Pezzi, J.C., Lopes, R.P., Teixeira, A.L., Bauer, M.E., Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin. Neurosci. 63 (2009), 202–208, 10.1111/j.1440-1819.2008.01918.x.
89. Green, R.C., Cupples, L.A., Kurz, A., Auerbach, S., Go, R., Sadovnick, D., Duara, R., Kukull, W.A., Chui, H., Edeki, T., Griffith, P.A., Friedland, R.P., Bachman, D., Farrer, L., Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch. Neurol. 60 (2003), 753–759, 10.1001/archneur.60.5.753.
90. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S.K., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.-C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J., TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368 (2013), 117–127, 10.1056/NEJMoa1211851.
91. Guillot-Sestier, M.V., Doty, K.R., Gate, D., Rodriguez, J., Leung, B.P., Rezai-Zadeh, K., Town, T., Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology article Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85 (2015), 1–15, 10.1016/j.neuron.2014.12.068.
92. Gulaj, E., Pawlak, K., Bien, B., Pawlak, D., Kynurenine and its metabolites in Alzheimer's disease patients. Adv. Med. Sci. 55 (2010), 204–211, 10.2478/v10039-010-0023-6.
93. Hart, B., Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 12 (1988), 123–137.
94. Hauser, P.S., Ryan, R.O., Impact of apolipoprotein E on Alzheimer's disease. Curr. Alzheimer Res. 10 (2013), 809–817, 10.2174/15672050113109990156.
95. Hellwig, S., Heinrich, A., Biber, K., The brain's best friend: microglial neurotoxicity revisited. Front. Cell. Neurosci., 7, 2013, 71, 10.3389/fncel.2013.00071.
96. Heneka, M.T., Kummer, M.P., Latz, E., Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14 (2014), 463–477, 10.1038/nri3705.
97. Heneka, M.T., Carson, M.J., Khoury, J. El., Landreth, G.E., Brosseron, F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., Herrup, K., Frautschy, S.A., Finsen, B., Brown, G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G.C., Town, T., Morgan, D., Shinohara, M.L., Perry, V.H., Holmes, C., Bazan, N.G., Brooks, D.J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D.T., Kummer, M.P., Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14 (2015), 388–405, 10.1016/S1474-4422(15)70016-5.
98. Heneka, M.T., Golenbock, D.T., Latz, E., Innate immunity in Alzheimer's disease. Nat. Immunol. 16 (2015), 229–236, 10.1038/ni.3102.
99. Hickman, S.E., Allison, E.K., El Khoury, J., Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28 (2008), 8354–8360, 10.1523/JNEUROSCI.0616-08.2008.
100. Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., Perry, V.H., Systemic inflammation and disease progression in Alzheimer disease. Neurology 73 (2009), 768–774, 10.1212/WNL.0b013e3181b6bb95.
101. Holsinger, R.M., Schnarr, J., Henry, P., Castelo, V.T., Fahnestock, M., Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 76 (2000), 347–354.
102. Holthoff, V.A., Beuthien-Baumann, B., Kalbe, E., Lüdecke, S., Lenz, O., Zündorf, G., Spirling, S., Schierz, K., Winiecki, P., Sorbi, S., Herholz, K., Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol. Psychiatry 57 (2005), 412–421, 10.1016/j.biopsych.2004.11.035.
103. Holtzheimer, P.E., Mayberg, H.S., Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 34 (2011), 1–9, 10.1016/j.tins.2010.10.004.
104. Hoshaw, B.A., Hill, T.I., Crowley, J.J., Malberg, J.E., Khawaja, X., Rosenzweig-Lipson, S., Schechter, L.E., Lucki, I., Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission. Eur. J. Pharmacol. 594 (2008), 109–116, 10.1016/j.ejphar.2008.07.023.
105. Hsieh, C.L., Koike, M., Spusta, S.C., Niemi, E.C., Yenari, M., Nakamura, M.C., Seaman, W.E., A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J. Neurochem. 109 (2009), 1144–1156, 10.1111/j.1471-4159.2009.06042.x.
106. Hu, X., Leak, R.K., Shi, Y., Suenaga, J., Gao, Y., Zheng, P., Chen, J., Microglial and macrophage polarization—new prospects for brain repair. Nat. Rev. Neurol. 11 (2014), 56–64, 10.1038/nrneurol.2014.207.
107. Hurt, C., Bhattacharyya, S., Burns, A., Camus, V., Liperoti, R., Marriott, A., Nobili, F., Robert, P., Tsolaki, M., Vellas, B., Verhey, F., Byrne, E.J., Patient and caregiver perspectives of quality of life in dementia: an investigation of the relationship to behavioural and psychological symptoms in dementia. Dement. Geriatr. Cogn. Disord. 26 (2008), 138–146, 10.1159/000149584.
108. Irwin, M.R., Miller, A.H., Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 21 (2007), 374–383, 10.1016/j.bbi.2007.01.010.
109. Jacobs, B.L., van Praag, H., Gage, F.H., Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry 5 (2000), 262–269, 10.1038/sj.mp.4000712.
110. Janzing, J.G.E., Hooijer, C., Van ’T Hof, M.A., Zitman, F.G., Depression in subjects with and without dementia: a comparison using GMS-AGECAT. Int. J. Geriatr. Psychiatry 17 (2002), 1–5, 10.1002/gps.526.
111. Jay, T.R., Miller, C.M., Cheng, P.J., Graham, L.C., Bemiller, S., Broihier, M.L., Xu, G., Margevicius, D., Karlo, J.C., Sousa, G.L., Cotleur, A.C., Butovsky, O., Bekris, L., Staugaitis, S.M., Leverenz, J.B., Pimplikar, S.W., Landreth, G.E., Howell, G.R., Ransohoff, R.M., Lamb, B.T., TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J. Exp. Med. 212 (2015), 287–295, 10.1084/jem.20142322.
112. Jin, K., Peel, A.L., Mao, X.O., Xie, L., Cottrell, B.A., Henshall, D.C., Greenberg, D.A., Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 343–347, 10.1073/pnas.2634794100.
113. Johansson, J.U., Woodling, N.S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H.D., Mhatre, S.D., Loui, T., Andreasson, K.I., Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J. Clin. Invest. 125 (2014), 350–364, 10.1172/JCI77487.
114. Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., Rujescu, D., Hampel, H., Giegling, I., Andreassen, O.A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, A., Ikram, M.A., van Duijn, C.M., Thorsteinsdottir, U., Kong, A., Stefansson, K., Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368 (2013), 107–116, 10.1056/NEJMoa1211103.
115. Jorge, R.E., Robinson, R.G., Moser, D., Tateno, A., Crespo-Facorro, B., Arndt, S., Major depression following traumatic brain injury. Arch. Gen. Psychiatry 61 (2004), 42–50, 10.1001/archpsyc.61.1.42.
116. Kales, H.C., Gitlin, L.N., Lyketsos, C.G., Assessment and management of behavioral and psychological symptoms of dementia. BMJ, 350, 2015, h369, 10.1136/bmj.h369.
117. Kang, J.Y., Lee, J.S., Kang, H., Lee, H.-W., Kim, Y.K., Jeon, H.J., Chung, J.-K., Lee, M.C., Cho, M.J., Lee, D.S., Regional cerebral blood flow abnormalities associated with apathy and depression in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26 (2012), 217–224, 10.1097/WAD.0b013e318231e5fc.
118. Karch, C.M., Cruchaga, C., Goate, A.M., Alzheimer's disease genetics: from the bench to the clinic. Neuron 83 (2014), 11–26, 10.1016/j.neuron.2014.05.041.
119. Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.M., Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 109 (2002), 143–148, 10.1016/S0165-1781(02)00005-7.
120. Kataoka, K., Hashimoto, H., Kawabe, J., Higashiyama, S., Akiyama, H., Shimada, A., Kai, T., Inoue, K., Shiomi, S., Kiriike, N., Frontal hypoperfusion in depressed patients with dementia of Alzheimer type demonstrated on 3DSRT. Psychiatry Clin. Neurosci. 64 (2010), 293–298, 10.1111/j.1440-1819.2010.02083.x.
121. Katon, W., Pedersen, H.S., Ribe, A.R., Fenger-Grøn, M., Davydow, D., Waldorff, F.B., Vestergaard, M., Effect of depression and diabetes mellitus on the risk for dementia. JAMA Psychiatry, 72, 2015, 612, 10.1001/jamapsychiatry.2015.0082.
122. Kempermann, G., Regulation of adult hippocampal neurogenesis – implications for novel theories of major depression. Bipolar Disord. 4 (2002), 17–33, 10.1034/j.1399-5618.2002.40101.x.
123. Kempermann, G., Kronenberg, G., Depressed new neurons – adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol. Psychiatry 54 (2003), 499–503, 10.1016/S0006-3223(03)00319-6.
124. Kent, S., Bluthé, R.M., Kelley, K.W., Dantzer, R., Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 13 (1992), 24–28, 10.1016/0165-6147(92)90012-U.
125. Khemka, V.K., Ganguly, A., Bagchi, D., Ghosh, A., Bir, A., Biswas, A., Chattopadhyay, S., Chakrabarti, S., Raised serum proinflammatory cytokines in Alzheimer's disease with depression. Aging Dis. 5 (2014), 170–176, 10.14336/AD.2014.0500170.
126. Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E.G., Wieghofer, P., Heinrich, A., Riemke, P., Hölscher, C., Müller, D.N., Luckow, B., Brocker, T., Debowski, K., Fritz, G., Opdenakker, G., Diefenbach, A., Biber, K., Heikenwalder, M., Geissmann, F., Rosenbauer, F., Prinz, M., Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 16 (2013), 273–280, 10.1038/nn.3318.
127. Kim, H.J., Kim, W., Kong, S.Y., Antidepressants for neuro-regeneration: from depression to Alzheimer's disease. Arch. Pharm. Res. 36 (2013), 1279–1290, 10.1007/s12272-013-0238-8.
128. Klempin, F., Beis, D., Mosienko, V., Kempermann, G., Bader, M., Alenina, N., Serotonin is required for exercise-induced adult hippocampal neurogenesis. J. Neurosci. 33 (2013), 8270–8275, 10.1523/JNEUROSCI.5855-12.2013.
129. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausén, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Långström, B., Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004), 306–319, 10.1002/ana.20009.
130. Knesevich, J.W., Martin, R.L., Berg, L., Danziger, W., Preliminary report on affective symptoms in the early stages of senile dementia of the Alzheimer type. Am. J. Psychiatry 140 (1983), 233–235.
131. Kobayashi, K., Imagama, S., Ohgomori, T., Hirano, K., Uchimura, K., Sakamoto, K., Hirakawa, A., Takeuchi, H., Suzumura, A., Ishiguro, N., Kadomatsu, K., Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis., 4, 2013, e525, 10.1038/cddis.2013.54.
132. Köhler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., Krogh, J., Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry, 71, 2014, 1381, 10.1001/jamapsychiatry.2014.1611.
133. Kohman, R.A., DeYoung, E.K., Bhattacharya, T.K., Peterson, L.N., Rhodes, J.S., Wheel running attenuates microglia proliferation and increases expression of a proneurogenic phenotype in the hippocampus of aged mice. Brain Behav. Immun. 26 (2012), 803–810, 10.1016/j.bbi.2011.10.006.
134. Kohman, R.A., Bhattacharya, T.K., Wojcik, E., Rhodes, J.S., Exercise reduces activation of microglia isolated from hippocampus and brain of aged mice. J. Neuroinflamm., 10, 2013, 114, 10.1186/1742-2094-10-114.
135. Kolodziejczak, M., Béchade, C., Gervasi, N., Irinopoulou, T., Banas, S.M., Cordier, C., Rebsam, A., Roumier, A., Maroteaux, L., Serotonin modulates developmental microglia via 5-HT 2B receptors: potential implication during synaptic refinement of retinogeniculate projections. ACS Chem. Neurosci. 6 (2015), 1219–1230, 10.1021/cn5003489.
136. Kopczak, A., Stalla, G.K., Uhr, M., Lucae, S., Hennings, J., Ising, M., Holsboer, F., Kloiber, S., IGF-I in major depression and antidepressant treatment response. Eur. Neuropsychopharmacol. 25 (2015), 864–872, 10.1016/j.euroneuro.2014.12.013.
137. Krabbe, G., Matyash, V., Pannasch, U., Mamer, L., Boddeke, H.W.G.M., Kettenmann, H., Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain Behav. Immun. 26 (2012), 419–428, 10.1016/j.bbi.2011.12.002.
138. Kreisel, T., Frank, M.G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M.V., Maier, S.F., Yirmiya, R., Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol. Psychiatry 19 (2014), 699–709, 10.1038/mp.2013.155.
139. Krstic, D., Knuesel, I., Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 9 (2013), 25–34, 10.1038/nrneurol.2012.236.
140. Lacasse, J.R., Leo, J., Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med., 2005, 10.1371/journal.pmed.0020392.
141. Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y.C., Kriz, J., Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27 (2007), 2596–2605, 10.1523/JNEUROSCI.5360-06.2007.
142. Lapchak, P.A., Araujo, D.M., Hefti, F., Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience 53 (1993), 297–301 0306-4522(93)90196-M [pii].
143. Laske, C., Stransky, E., Leyhe, T., Eschweiler, G.W., Maetzler, W., Wittorf, A., Soekadar, S., Richartz, E., Koehler, N., Bartels, M., Buchkremer, G., Schott, K., BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J. Psychiatr. Res. 41 (2007), 387–394, 10.1016/j.jpsychires.2006.01.014.
144. Laws, S.M., Perneczky, R., Wagenpfeil, S., Müller, U., Förstl, H., Martins, R.N., Kurz, A., Riemenschneider, M., TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum. Mutat. 26 (2005), 29–35, 10.1002/humu.20180.
145. Lazarov, O., Marr, R.A., Of mice and men: neurogenesis, cognition, and Alzheimer's disease. Front. Aging Neurosci. 5 (2013), 1–8, 10.3389/fnagi.2013.00043.
146. Ledo, J.H., Azevedo, E.P., Clarke, J.R., Ribeiro, F.C., Figueiredo, C.P., Foguel, D., De Felice, F.G., Ferreira, S.T., Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice. Mol. Psychiatry 18 (2013), 1053–1054, 10.1038/mp.2012.168.
147. Lee, H.B., Lyketsos, C.G., Depression in Alzheimer's disease: heterogeneity and related issues. Biol. Psychiatry 54 (2003), 353–362, 10.1016/S0006-3223(03)00543-2.
148. Lee, Y.-K., Hou, S.-W., Lee, C.-C., Hsu, C.-Y., Huang, Y.-S., Su, Y.-C., Increased Risk of Dementia in Patients with Mild Traumatic Brain Injury: A Nationwide Cohort Study. PLoS One, 8, 2013, e62422, 10.1371/journal.pone.0062422.
149. Levy-Cooperman, N., Burhan, A.M., Rafi-Tari, S., Kusano, M., Ramirez, J., Caldwell, C., Black, S.E., Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. J. Psychiatry Neurosci. 33 (2008), 218–226.
150. Li, Y., Du, X.F., Liu, C.S., Wen, Z.L., Du, J.L., Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo. Dev. Cell 23 (2012), 1189–1202, 10.1016/j.devcel.2012.10.027.
151. Lin, F., Suhr, J., Diebold, S., Heffner, K.L., Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology 42 (2014), 118–123, 10.1016/j.psyneuen.2014.01.006.
152. Lu, B., Nagappan, G., Guan, X., Nathan, P.J., Wren, P., BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci. 14 (2013), 401–416 nrn3505 [pii]⧹r10.1038/nrn3505.
153. Luo, X.-G., Ding, J.-Q., Chen, S.-D., Microglia in the aging brain: relevance to neurodegeneration. Mol. Neurodegener., 5, 2010, 12, 10.1186/1750-1326-5-12.
154. Lyketsos, C.G., Olin, J., Depression in Alzheimer's disease: overview and treatment. Biol. Psychiatry 52 (2002), 243–252, 10.1016/S0006-3223(02)01348-3.
155. Lyketsos, C.G., Steinberg, M., Tschanz, J.T., Norton, M.C., Steffens, D.C., Breitner, J.C.S., Mental and behavioral disturbance in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 157 (2000), 708–714, 10.1176/appi.ajp.157.5.708.
156. Lyketsos, C.G., Lopez, O., Jones, B., Fitzpatrick, A.L., Breitner, J., DeKosky, S., Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288 (2002), 1475–1483, 10.1001/jama.288.12.1475.
157. Lyketsos, C.G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C.D., Munro, C., Baker, A.S., Sheppard, J.-M.E., Frangakis, C., Brandt, J., Rabins, P.V., Treating depression in Alzheimer disease. Arch. Gen. Psychiatry, 60, 2003, 737, 10.1001/archpsyc.60.7.737.
158. Lyketsos, C.G., Carrillo, M.C., Ryan, J.M., Khachaturian, A.S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., Miller, D.S., Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's Dement., 2011, 10.1016/j.jalz.2011.05.2410.
159. Lynch, M.A., The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology 141 (2014), 292–301, 10.1111/imm.12156.
160. Macchi, F., Homberg, J.R., Calabrese, F., Zecchillo, C., Racagni, G., Riva, M.A., Molteni, R., Altered inflammatory responsiveness in serotonin transporter mutant rats. J. Neuroinflamm., 10, 2013, 116, 10.1186/1742-2094-10-116.
161. Maddison, D.C., Giorgini, F., The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol., 44, 2015, 10.1016/j.semcdb.2015.03.002.
162. Maes, M., Leonard, B.E., Myint, A.M., Kubera, M., Verkerk, R., The new “5-HT” hypothesis of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 (2011), 702–721, 10.1016/j.pnpbp.2010.12.017.
163. Malberg, J.E., Platt, B., Rizzo, S.J.S., Ring, R.H., Lucki, I., Schechter, L.E., Rosenzweig-Lipson, S., Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32 (2007), 2360–2368, 10.1038/sj.npp.1301358.
164. Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., Hall, W.J., Fisher, S.G., Peterson, D.R., Haley, J.M., Nazar, M.D., Rich, S.A., Berlau, D.J., Peltz, C.B., Tan, M.T., Kawas, C.H., Federoff, H.J., Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20 (2014), 415–418, 10.1038/nm.3466.
165. Mårtensson, U., Nässberger, L., Influence of antidepressants on mitogen stimulation of human lymphocytes. Toxicol. In Vitro 7 (1993), 241–245, 10.1016/0887-2333(93)90007-R.
166. Martínez, A., Alcántara, S., Borrell, V., Del Río, J.A., Blasi, J., Otal, R., Campos, N., Boronat, A., Barbacid, M., Silos-Santiago, I., Soriano, E., TrkB and TrkC signaling are required for maturation and synaptogenesis of hippocampal connections. J. Neurosci. 18 (1998), 7336–7350.
167. Mattson, M.P., Maudsley, S., Martin, B., A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res. Rev. 3 (2004), 445–464, 10.1016/j.arr.2004.08.001.
168. Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., Bateman, R.J., Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 330, 2010, 1774, 10.1126/science.1197623.
169. Merriam, A.E., Aronson, M.K., Gaston, P., Wey, S.L., Katz, I., The psychiatric symptoms of Alzheimer's disease. J. Am. Geriatr. Soc. 36 (1988), 7–12.
170. Michaud, M., Balardy, L., Moulis, G., Gaudin, C., Peyrot, C., Vellas, B., Cesari, M., Nourhashemi, F., Proinflammatory cytokines, aging, and age-related diseases. J. Am. Med. Dir. Assoc. 14 (2013), 877–882, 10.1016/j.jamda.2013.05.009.
171. Mitschelen, M., Yan, H., Farley, J.A., Warrington, J.P., Han, S., Hereñú, C.B., Csiszar, A., Ungvari, Z., Bailey-Downs, L.C., Bass, C.E., Sonntag, W.E., Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience 185 (2011), 50–60, 10.1016/j.neuroscience.2011.04.032.
172. Mittelbronn, M., The M1/M2 immune polarization concept in microglia: a fair transfer?. Neuroimmunol. Neuroinflamm., 1, 2014, 6, 10.4103/2347-8659.135567.
173. Modrego, P.J., Ferrández, J., Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch. Neurol. 61 (2004), 1290–1293, 10.1001/archneur.61.8.1290.
174. Molendijk, M.L., Spinhoven, P., Polak, M., Bus, B.A.A., Penninx, B.W.J.H., Elzinga, B.M., Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol. Psychiatry 19 (2014), 791–800, 10.1038/mp.2013.105.
175. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., O'Neill, C., Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31 (2010), 224–243, 10.1016/j.neurobiolaging.2008.04.002.
176. Mondelli, V., Cattaneo, A., Murri, M.B., Forti, M., Di Handley, R., Hepgul, N., Miorelli, A., Navari, S., Papadopoulos, A.S., Aitchison, K.J., Morgan, C., Murray, R.M., Dazzan, P., Pariante, C.M., Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 72 (2011), 1677–1684, 10.4088/JCP.10m06745.
177. Monje, M.L., Toda, H., Palmer, T.D., Inflammatory blockade restores adult hippocampal neurogenesis. Science 302 (2003), 1760–1765, 10.1126/science.1088417.
178. Morales, I., Guzmán-Martínez, L., Cerda-Troncoso, C., Farías, G.A., Maccioni, R.B., Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell. Neurosci., 8, 2014, 112, 10.3389/fncel.2014.00112.
179. Morgan, S.C., Taylor, D.L., Pocock, J.M., Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades. J. Neurochem. 90 (2004), 89–101, 10.1111/j.1471-4159.2004.02461.x.
180. Mu, Y., Gage, F.H., Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegener., 6, 2011, 85, 10.1186/1750-1326-6-85.
181. Müller, N., COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs 11 (2010), 31–42.
182. Müller, N., Schwarz, M.J., The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 12 (2007), 988–1000, 10.1038/sj.mp.4002006.
183. Myint, A.M., Kim, Y.K., Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 61 (2003), 519–525, 10.1016/S0306-9877(03)00207-X.
184. Nakanishi, M., Niidome, T., Matsuda, S., Akaike, A., Kihara, T., Sugimoto, H., Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur. J. Neurosci. 25 (2007), 649–658, 10.1111/j.1460-9568.2007.05309.x.
185. Naranjo, D.M., Fisher, L., Arean, P.A., Hessler, D., Mullan, J., Patients with type 2 diabetes at risk for major depressive disorder over time. Ann. Fam. Med. 9 (2011), 115–120, 10.1370/afm.1212.
186. Nelson, J.C., Diagnosing and treating depression in the elderly. J. Clin. Psychiatry 62 (2001), 18–22.
187. Nelson, J.C., Devanand, D.P., A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J. Am. Geriatr. Soc. 59 (2011), 577–585, 10.1111/j.1532-5415.2011.03355.x.
188. Ng, F., Berk, M., Dean, O., Bush, A.I., Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11 (2008), 851–876, 10.1017/S1461145707008401.
189. Nimmerjahn, A., Kirchhoff, F., Helmchen, F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Neuroforum 11 (2005), 95–96, 10.1126/science.1110647.
190. Norden, D.M., Muccigrosso, M.M., Godbout, J.P., Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease. Neuropharmacology 96 (2015), 29–41, 10.1016/j.neuropharm.2014.10.028.
191. O'Connor, J.C., Lawson, M.A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522, 10.1038/sj.mp.4002148.
192. Okereke, O.I., Kang, J.H., Ma, J., Gaziano, J.M., Grodstein, F., Midlife plasma insulin-like growth factor I and cognitive function in older men. J. Clin. Endocrinol. Metab. 91 (2006), 4306–4312, 10.1210/jc.2006-1325.
193. Olin, J.T., Schneider, L.S., Katz, I.R., Meyers, B.S., Alexopoulos, G.S., Breitner, J.C., Bruce, M.L., Caine, E.D., Cummings, J.L., Devanand, D.P., Krishnan, K.R.R., Lyketsos, C.G., Lyness, J.M., Rabins, P.V., Reynolds, C.F., Rovner, B.W., Steffens, D.C., Tariot, P.N., Lebowitz, B.D., Provisional diagnostic criteria for depression of Alzheimer disease. Am. J. Geriatr. Psychiatry 10 (2002), 125–128, 10.1097/00019442-200203000-00003.
194. Orre, M., Kamphuis, W., Osborn, L.M., Jansen, A.H.P., Kooijman, L., Bossers, K., Hol, E.M., Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. Neurobiol. Aging 35 (2014), 2746–2760, 10.1016/j.neurobiolaging.2014.06.004.
195. Oshima, E., Terada, S., Sato, S., Ikeda, C., Oda, K., Inoue, S., Kawada, K., Yokota, O., Uchitomi, Y., Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors. Psychiatry Res. Neuroimaging 224 (2014), 319–323, 10.1016/j.pscychresns.2014.10.008.
196. Ott, A., Stolk, R.P., Hofman, A., Van Harskamp, F., Grobbee, D.E., Breteler, M.M.B., Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39 (1996), 1392–1397, 10.1007/s001250050588.
197. Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., Breteler, M.M., Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53 (1999), 1937–1942, 10.1016/S0140-6736(97)07541-7.
198. Ownby, R.L., Crocco, E., Acevedo, A., John, V., Loewenstein, D., Depression and risk for Alzheimer disease. Arch. Gen. Psychiatry 63 (2006), 530–538.
199. Palmqvist, S., Sarwari, A., Wattmo, C., Bronge, L., Zhang, Y., Wahlund, L.O., Nägga, K., Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 32 (2011), 417–423, 10.1159/000335778.
200. Panza, F., Frisardi, V., Capurso, C., D'Introno, A., Colacicco, A.M., Imbimbo, B.P., Santamato, A., Vendemiale, G., Seripa, D., Pilotto, A., Capurso, A., Solfrizzi, V., Late-life depression, mild cognitive impairment, and dementia: possible continuum?. Am. J. Geriatr. Psychiatry 18 (2010), 98–116, 10.1097/JGP.0b013e3181b0fa13.
201. Paolicelli, R.C., Gross, C.T., Microglia in development: linking brain wiring to brain environment. Neuron Glia Biol. 7 (2011), 77–83, 10.1017/S1740925X12000105.
202. Paolicelli, R.C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, T.A., Guiducci, E., Dumas, L., Ragozzino, D., Gross, C.T., Synaptic pruning by microglia is necessary for normal brain development. Science 333 (2011), 1456–1458, 10.1126/science.1202529.
203. Pariante, C.M., Lightman, S.L., The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 31 (2008), 464–468, 10.1016/j.tins.2008.06.006.
204. Park, S.-E., Dantzer, R., Kelley, K.W., McCusker, R.H., Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J. Neuroinflamm., 8, 2011, 12, 10.1186/1742-2094-8-12.
205. Parkhurst, C.N., Yang, G., Ninan, I., Savas, J.N., Yates, J.R., Lafaille, J.J., Hempstead, B.L., Littman, D.R., Gan, W.B., Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155 (2013), 1596–1609, 10.1016/j.cell.2013.11.030.
206. Parpura, V., Zorec, R., Gliotransmission: exocytotic release from astrocytes. Brain Res. Rev. 63 (2010), 83–92, 10.1016/j.brainresrev.2009.11.008.
207. Pascoe, M.C., Crewther, S.G., Carey, L.M., Crewther, D.P., Inflammation and depression: why poststroke depression may be the norm and not the exception. Int. J. Stroke 6 (2011), 128–135, 10.1111/j.1747-4949.2010.00565.x.
208. Paslakis, G., Blum, W.F., Deuschle, M., Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression. Med. Hypotheses 79 (2012), 222–225, 10.1016/j.mehy.2012.04.045.
209. Peng, S., Wuu, J., Mufson, E.J., Fahnestock, M., Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 93 (2005), 1412–1421, 10.1111/j.1471-4159.2005.03135.x.
210. Perry, V.H., Holmes, C., Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10 (2014), 217–224, 10.1038/nrneurol.2014.38.
211. Perry, V.H., Cunningham, C., Holmes, C., Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7 (2007), 161–167, 10.1038/nri2015.
212. Pocock, J.M., Kettenmann, H., Neurotransmitter receptors on microglia. Trends Neurosci. 30 (2007), 527–535, 10.1016/j.tins.2007.07.007.
213. Porta-Etessam, J., Tobaruela-González, J.L., Rabes-Berendes, C., Depression in patients with moderate Alzheimer disease. Alzheimer Dis. Assoc. Disord. 25 (2011), 317–325, 10.1097/WAD.0b013e31820e7c45.
214. Powell, T.R., Schalkwyk, L.C., Heffernan, A.L., Breen, G., Lawrence, T., Price, T., Farmer, A.E., Aitchison, K.J., Craig, I.W., Danese, A., Lewis, C., McGuffin, P., Uher, R., Tansey, K.E., D'Souza, U.M., Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur. Neuropsychopharmacol. 23 (2013), 1105–1114, 10.1016/j.euroneuro.2012.09.009.
215. Prinz, M., Priller, J., Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15 (2014), 300–312, 10.1038/nrn3722.
216. Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006), 24–31, 10.1016/j.it.2005.11.006.
217. Rauskolb, S., Zagrebelsky, M., Dreznjak, A., Deogracias, R., Matsumoto, T., Wiese, S., Erne, B., Sendtner, M., Schaeren-Wiemers, N., Korte, M., Barde, Y.-A., Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. J. Neurosci. 30 (2010), 1739–1749, 10.1523/JNEUROSCI.5100-09.2010.
218. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., Pollmächer, T., Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001), 445–452, 10.1001/archpsyc.58.5.445.
219. Renault, P.F., Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med., 147, 1987, 1577, 10.1001/archinte.1987.00370090055011.
220. Ribeiro Xavier, A.L., Kress, B.T., Goldman, S.A., Lacerda de Menezes, J.R., Nedergaard, M., A distinct population of microglia supports adult neurogenesis in the subventricular zone. J. Neurosci. 35 (2015), 11848–11861, 10.1523/JNEUROSCI.1217-15.2015.
221. Richard, E., Reitz, C., Honig, L.H., Schupf, N., Tang, M.X., Manly, J.J., Mayeux, R., Devanand, D., Luchsinger, J.A., Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol., 70, 2013, 383, 10.1001/jamaneurol.2013.603.
222. Rivest, S., TREM2 enables amyloid β clearance by microglia. Cell Res. 25 (2015), 535–536, 10.1038/cr.2015.37.
223. Roberts, R., Knopman, D.S., Classification and epidemiology of MCI. Clin. Geriatr. Med. 29 (2013), 753–772, 10.1016/j.cger.2013.07.003.
224. Roberts, K.F., Elbert, D.L., Kasten, T.P., Patterson, B.W., Sigurdson, W.C., Connors, R.E., Ovod, V., Munsell, L.Y., Mawuenyega, K.G., Miller-Thomas, M.M., Moran, C.J., Cross, D.T., Derdeyn, C.P., Bateman, R.J., Amyloid-β efflux from the central nervous system into the plasma. Ann. Neurol. 76 (2014), 837–844, 10.1002/ana.24270.
225. Rodríguez, J.J., Noristani, H.N., Verkhratsky, A., The serotonergic system in ageing and Alzheimer's disease. Prog. Neurobiol. 99 (2012), 15–41, 10.1016/j.pneurobio.2012.06.010.
226. Roumestan, C., Michel, A., Bichon, F., Portet, K., Detoc, M., Henriquet, C., Jaffuel, D., Mathieu, M., Anti-inflammatory properties of desipramine and fluoxetine. Respir. Res., 8, 2007, 35, 10.1186/1465-9921-8-35.
227. Ruhé, H.G., Mason, N.S., Schene, A.H., Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12 (2007), 331–359, 10.1038/sj.mp.4001949.
228. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163 (2006), 1905–1917, 10.1176/appi.ajp.163.11.1905.
229. Sabri, O., Seibyl, J., Rowe, C., Barthel, H., Beta-amyloid imaging with florbetaben. Clin. Transl. Imaging 3 (2015), 13–26, 10.1007/s40336-015-0102-6.
230. Sacre, S., Medghalchi, M., Gregory, B., Brennan, F., Williams, R., Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 62 (2010), 683–693, 10.1002/art.27304.
231. Sadovnick, A.D., Remick, R.A., Allen, J., Swartz, E., Yee, I.M., Eisen, K., Farquhar, R., Hashimoto, S.A., Hooge, J., Kastrukoff, L.F., Morrison, W., Nelson, J., Oger, J., Paty, D.W., Depression and multiple sclerosis. Eur. Psychiatry J. Assoc. Eur. Psychiatry 46 (1997), 628–632, 10.1212/WNL.46.3.628.
232. Saunders, A.M., Strittmatter, W.J., Schmechel, D., George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R., Alberts, M.J., Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993), 1467–1472, 10.1212/WNL.43.8.1467.
233. Schildkraut, J.J., The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122 (1965), 509–522, 10.1176/appi.ajp.122.5.509.
234. Sciacca, F., Ferri, C., Licastro, F., Veglia, F., Biunno, I., Gavazzi, A., Calabrese, E., Martinelli Boneschi, F., Sorbi, S., Mariani, C., Franceschi, M., Grimaldi, L.M., Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease. Neurobiol. Aging 24 (2003), 927–931, 10.1016/S0197-4580(03)00011-3.
235. Sepehry, A.A., Lee, P.E., Hsiung, G.Y.R., Beattie, B.L., Jacova, C., Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging 29 (2012), 793–806, 10.1007/s40266-012-0012-5.
236. Setiawan, E., Wilson, A.A., Mizrahi, R., Rusjan, P.M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J.L., Rekkas, P.V., Houle, S., Meyer, J.H., Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry, 72, 2015, 268, 10.1001/jamapsychiatry.2014.2427.
237. Sheline, Y.I., West, T., Yarasheski, K., Swarm, R., Jasielec, M.S., Fisher, J.R., Ficker, W.D., Yan, P., Xiong, C., Frederiksen, C., Grzelak, M.V., Chott, R., Bateman, R.J., Morris, J.C., Mintun, M.A., Lee, J.-M., Cirrito, J.R., An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci. Transl. Med., 6, 2014, 236re4, 10.1126/scitranslmed.3008169.
238. Smith, R.S., The macrophage theory of depression. Med. Hypotheses 35 (1991), 298–306, 10.1016/0306-9877(91)90272-Z.
239. Soczynska, J.K., Mansur, R.B., Brietzke, E., Swardfager, W., Kennedy, S.H., Woldeyohannes, H.O., Powell, A.M., Manierka, M.S., McIntyre, R.S., Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav. Brain Res., 2012, 10.1016/j.bbr.2012.07.026.
240. Son, J.H., Han, D.H., Min, K.J., Kee, B.S., Correlation between gray matter volume in the temporal lobe and depressive symptoms in patients with Alzheimer's disease. Neurosci. Lett. 548 (2013), 15–20, 10.1016/j.neulet.2013.05.021.
241. Sonntag, W.E., Deak, F., Ashpole, N., Toth, P., Csiszar, A., Freeman, W., Ungvari, Z., Insulin-like growth factor-1 in CNS and cerebrovascular aging. Front. Aging Neurosci., 5, 2013, 27, 10.3389/fnagi.2013.00027.
242. Starkstein, S.E., Jorge, R., Mizrahi, R., Robinson, R.G., The construct of minor and major depression in Alzheimer's disease. Am. J. Psychiatry 162 (2005), 2086–2093, 10.1176/appi.ajp.162.11.2086.
243. Steinberg, M., Shao, H., Zandi, P., Lyketsos, C.G., Welsh-bohmer, K.A., Norton, M.C., Breitner, J.C.S., Steffens, D.C., Tschanz, J.T., Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int. J. Geriatr. Psychiatry 23 (2008), 170–177, 10.1002/gps.
244. Steiner, J., Walter, M., Gos, T., Guillemin, G.J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., Zu Schwabedissen, L., Bogerts, B., Myint, A.-M., Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J. Neuroinflamm., 8, 2011, 94, 10.1186/1742-2094-8-94.
245. Su, F., Yi, H., Xu, L., Zhang, Z., Fluoxetine and S-citalopram inhibit M1 activation and promote M2 activation of microglia in vitro. Neuroscience 294 (2015), 60–68, 10.1016/j.neuroscience.2015.02.028.
246. Sun, L.Y., Hippocampal IGF-1 expression, neurogenesis and slowed aging: clues to longevity from mutant mice. Age (Omaha) 28 (2006), 181–189, 10.1007/s11357-006-9009-5.
247. Swardfager, W., Lanctt, K., Rothenburg, L., Wong, A., Cappell, J., Herrmann, N., A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68 (2010), 930–941, 10.1016/j.biopsych.2010.06.012.
248. Szczêsny, E., OElusarczyk, J., Glombik, K., Budziszewska, B., Kubera, M., Lasoñz, W., Basta-Kaim, A., Possible contribution of IGF-1 to depressive disorder. Pharmacol. Rep. 65 (2013), 1622–1631.
249. Takahashi, K., Rochford, C.D.P., Neumann, H., Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201 (2005), 647–657, 10.1084/jem.20041611.
250. Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122 (2012), 1316–1338, 10.1172/JCI59903.
251. Taraz, M., Khatami, M., Dashti-khavidaki, S., Akhonzadeh, S., Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. Int. Immunopharmacol. 17 (2013), 917–923, 10.1016/j.intimp.2013.09.020.
252. Teng, E., Ringman, J.M., Ross, L.K., Mulnard, R.A., Dick, M.B., Bartzokis, G., Davies, H.D., Galasko, D., Hewett, L., Mungas, D., Reed, B.R., Schneider, L.S., Segal-Gidan, F., Yaffe, K., Cummings, J.L., Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am. J. Geriatr. Psychiatry 16 (2008), 469–477, 10.1097/JGP.0b013e318165dbae.
253. Terada, S., Oshima, E., Sato, S., Ikeda, C., Nagao, S., Hayashi, S., Hayashibara, C., Yokota, O., Uchitomi, Y., Depressive symptoms and regional cerebral blood flow in Alzheimer's disease. Psychiatry Res. 221 (2014), 86–91, 10.1016/j.pscychresns.2013.11.002.
254. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40, 10.1176/appi.ajp.163.1.28.
255. Turnbull, I.R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., Colonna, M., Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177 (2006), 3520–3524, 10.4049/jimmunol.177.6.3520.
256. Tynan, R.J., Weidenhofer, J., Hinwood, M., Cairns, M.J., Day, T.A., Walker, F.R., A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav. Immun. 26 (2012), 469–479, 10.1016/j.bbi.2011.12.011.
257. Ueno, M., Fujita, Y., Tanaka, T., Nakamura, Y., Kikuta, J., Ishii, M., Yamashita, T., Layer V cortical neurons require microglial support for survival during postnatal development. Nat. Neurosci. 16 (2013), 543–551, 10.1038/nn.3358.
258. Ulrich, J.D., Finn, M.B., Wang, Y., Shen, A., Mahan, T.E., Jiang, H., Stewart, F.R., Piccio, L., Colonna, M., Holtzman, D.M., Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener., 9, 2014, 20, 10.1186/1750-1326-9-20.
259. Vécsei, L., Szalárdy, L., Fülöp, F., Toldi, J., Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12 (2013), 64–82, 10.1038/nrd3793.
260. Ventriglia, M., Zanardini, R., Bonomini, C., Zanetti, O., Volpe, D., Pasqualetti, P., Gennarelli, M., Bocchio-Chiavetto, L., Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res. Int. 2013 (2013), 1–7, 10.1155/2013/901082.
261. Videbech, P., Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 161 (2004), 1957–1966, 10.1176/appi.ajp.161.11.1957.
262. Vilalta-Franch, J., Garre-Olmo, J., Lopez-Pousa, S., Turon-Estrada, A., Lozano-Gallego, M., Hernandez-Ferrandiz, M., Pericot-Nierga, I., Feijoo-Lorza, R., Comparison of different clinical diagnostic criteria for depression in Alzheimer disease. Am. J. Geriatr. Psychiatry 14 (2006), 589–597 doi: 10.1097/01.JGP.0000209396.15788.9d.
263. Viola, K.L., Sbarboro, J., Sureka, R., De, M., Bicca, M.A., Wang, J., Vasavada, S., Satpathy, S., Wu, S., Joshi, H., Velasco, P.T., MacRenaris, K., Waters, E.A., Lu, C., Phan, J., Lacor, P., Prasad, P., Dravid, V.P., Klein, W.L., Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat. Nanotechnol. 10 (2014), 91–98, 10.1038/nnano.2014.254.
264. Von Bernhardi, R., Tichauer, J.E., Eugenín, J., Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J. Neurochem. 112 (2010), 1099–1114, 10.1111/j.1471-4159.2009.06537.x.
265. Vukovic, J., Colditz, M.J., Blackmore, D.G., Ruitenberg, M.J., Bartlett, P.F., Microglia modulate hippocampal neural precursor activity in response to exercise and aging. J. Neurosci. 32 (2012), 6435–6443, 10.1523/JNEUROSCI.5925-11.2012.
266. Walker, F.R., A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology 67 (2013), 304–317, 10.1016/j.neuropharm.2012.10.002.
267. Walton, N.M., Sutter, B.M., Laywell, E.D., Levkoff, L.H., Kearns, S.M., Marshall, G.P., Scheffler, B., Steindler, D.A., Microglia instruct subventricular zone neurogenesis. Glia 54 (2006), 815–825, 10.1002/glia.20419.
268. Wang, T., TNF-alpha G308A polymorphism and the susceptibility to Alzheimer's Disease: an updated meta-analysis. Arch. Med. Res., 46(24–30), 2015, e1, 10.1016/j.arcmed.2014.12.006.
269. Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., Gilfillan, S., Krishnan, G.M., Sudhakar, S., Zinselmeyer, B.H., Holtzman, D.M., Cirrito, J.R., Colonna, M., TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160 (2015), 1061–1071, 10.1016/j.cell.2015.01.049.
270. Watanabe, T., Miyazaki, A., Katagiri, T., Yamamoto, H., Idei, T., Iguchi, T., Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J. Am. Geriatr. Soc. 53 (2005), 1748–1753, 10.1111/j.1532-5415.2005.53524.x.
271. Westwood, A.J., Beiser, A., Decarli, C., Harris, T.B., Chen, T.C., He, X.-M., Roubenoff, R., Pikula, A., Au, R., Braverman, L.E., Wolf, P.A., Vasan, R.S., Seshadri, S., Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology 82 (2014), 1613–1619, 10.1212/WNL.0000000000000382.
272. Wichers, M.C., Maes, M., The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J. Psychiatry Neurosci. 29 (2004), 11–17.
273. Wilcock, D.M., A changing perspective on the role of neuroinflammation in Alzheimer's disease. Int. J. Alzheimers. Dis. 2012 (2012), 1–7, 10.1155/2012/495243.
274. Wolkowitz, O.M., Wolf, J., Shelly, W., Rosser, R., Burke, H.M., Lerner, G.K., Reus, V.I., Nelson, J.C., Epel, E.S., Mellon, S.H., Serum BDNF levels before treatment predict SSRI response in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 (2011), 1623–1630, 10.1016/j.pnpbp.2011.06.013.
275. Yasutake, C., Kuroda, K., Yanagawa, T., Okamura, T., Yoneda, H., Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006), 402–406, 10.1007/s00406-006-0652-8.
276. Ye, S.M., Johnson, R.W., Increased interleukin-6 expression by microglia from brain of aged mice. J. Neuroimmunol. 93 (1999), 139–148, 10.1016/S0165-5728(98)00217-3.
277. Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Leirer, V.O., Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res. 17 (1982), 37–49, 10.1016/0022-3956(82)90033-4.
278. Yirmiya, R., Endotoxin produces a depressive-like episode in rats. Brain Res. 711 (1996), 163–174, 10.1016/0006-8993(95)01415-2.
279. Yirmiya, R., Rimmerman, N., Reshef, R., Depression as a microglial disease. Trends Neurosci. 38 (2015), 637–658, 10.1016/j.tins.2015.08.001.
280. Yu, H., Chen, Z., The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol. Sin. 32 (2011), 3–11, 10.1038/aps.2010.184.
281. Yu, D., Tao, B.-B., Yang, Y.-Y., Du, L.-S., Yang, S.-S., He, X.-J., Zhu, Y.-W., Yan, J.-K., Yang, Q., The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. J. Alzheimers. Dis. 43 (2015), 291–302, 10.3233/JAD-140414.
282. Yuan, H., Chen, R., Wu, L., Chen, Q., Hu, A., Zhang, T., Wang, Z., Zhu, X., The regulatory mechanism of neurogenesis by IGF-1 in adult mice. Mol. Neurobiol. 51 (2015), 512–522, 10.1007/s12035-014-8717-6.
283. Zhan, Y., Paolicelli, R.C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., Vyssotski, A.L., Bifone, A., Gozzi, A., Ragozzino, D., Gross, C.T., Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat. Neurosci. 17 (2014), 400–406, 10.1038/nn.3641.
284. Zhang, F., Zhou, H., Wilson, B.C., Shi, J.-S., Hong, J.-S., Gao, H.-M., Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat. Disord. 18 (2012), S213–S217, 10.1016/S1353-8020(11)70066-9.
285. Zheng, L.S., Hitoshi, S., Kaneko, N., Takao, K., Miyakawa, T., Tanaka, Y., Xia, H., Kalinke, U., Kudo, K., Kanba, S., Ikenaka, K., Sawamoto, K., Mechanisms for interferon-α-induced depression and neural stem cell dysfunction. Stem Cell Rep. 3 (2014), 73–84, 10.1016/j.stemcr.2014.05.015.
286. Zheng, L.-S., Kaneko, N., Sawamoto, K., Minocycline treatment ameliorates interferon-alpha-induced neurogenic defects and depression-like behaviors in mice. Front. Cell. Neurosci. 9 (2015), 1–10, 10.3389/fncel.2015.00005.
287. Ziebell, J.M., Morganti-Kossmann, M.C., Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 7 (2010), 22–30, 10.1016/j.nurt.2009.10.016.
288. Ziv, Y., Schwartz, M., Immune-based regulation of adult neurogenesis: implications for learning and memory. Brain Behav. Immun. 22 (2008), 167–176, 10.1016/j.bbi.2007.08.006.
289. Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., Kipnis, J., Schwartz, M., Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9 (2006), 268–275, 10.1038/nn1629.
290. Zubenko, G.S., Zubenko, W.N., McPherson, S., Spoor, E., Marin, D.B., Farlow, M.R., Smith, G.E., Geda, Y.E., Cummings, J.L., Petersen, R.C., Sunderland, T., A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am. J. Psychiatry 160 (2003), 857–866, 10.1176/appi.ajp.160.5.857.